

17 February 2010

Proposal to fund lignocaine urethral syringes

PHARMAC is seeking feedback on a proposal to list lignocaine gel 2% (10 ml urethral syringe) in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 May 2010 at a price and subsidy of \$43.26 per pack of 10, through an agreement with Pfizer New Zealand Limited.

Lignocaine is a local anaesthetic. The proposed listing would be in addition to the currently funded alternative product lignocaine gel 2% with chlorhexidine 0.05% (10 ml urethral syringe) and would be the same price and subsidy as the currently funded product.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by **Wednesday, 3 March 2010** to:

Geraldine MacGibbon
Therapeutic Group Manager
PHARMAC

Email: geraldine.macgibbon@pharmac.govt.nz
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.